Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
美国FDA批准:用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.